ArticleResearch and practice in thrombosis and haemostasis2025
The Patient-Reported Outcomes Measurement Information System perspective of adults with long-standing atypical hemolytic uremic syndrome.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy driven by a dysregulation of the complement system, disproportionately affecting the kidneys. While terminal complement blockade has reduced the risk of death and progression to end stage renal disease, patients face significant chronic health challenges. The patient experience in the current treatment era has not been well-characterized. Objectives: To evaluate patient-reported health outcomes (PRO) across global health domains, including physical and cognitive function and social isolation. Methods: We performed a cross-sectional analysis of adults with aHUS using validated National Institute of Health Patient-Reported Outcomes Measurement Information System instruments. Results: Compared with a normative reference population, our aHUS cohort ( Conclusion: In this first study of PROs in patients with long-standing aHUS in the era of complement-directed therapies, patients reported a chronically impaired global health status with reduced physical and cognitive function and higher levels of fatigue, anxiety, depression, and sleep disturbances compared with the general population. Our data underscore that aHUS is a multisystem disease that may be associated with persistent symptoms even during periods of hematologic and renal quiescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.